Epidermolysis
bullosa (EB), is
a rare genetic connective tissue skin disorder that causes blisters and allows
skin to become fragile. Blisters and areas of skin loss (erosions) occur in
response to minor injury or friction, such as rubbing or scratching. The
disease affects 1 out of every 20,000 births in the U.S. The symptoms of
epidermolysis bullosa are redness and heat around an open area of skin;
crusting on the wound surface; pus or yellow fluid discharge; red line or
streak under the skin that spreads away from the blistered area; wound; and
fever or chills.
Request
to Get the Sample Pages at:
Epidermolysis
bullosa can be diagnosed through skin biopsy, prenatal and genetic testing. In
order to treat the disease, surgical treatment or rehabilitation therapy can be
opted. It can also be managed by daily wound care, pain management, and
protective bandaging.
Access
Detailed Report Summary:
The drug
candidates of epidermolysis bullosa pipeline include, but not limited to, EB
101, FCX 007, and Diacerein. Some of the companies having drugs in the
epidermolysis bullosa therapeutics pipeline includes Abeona Therapeutics Inc.,
TWi Pharmaceuticals Inc. and Fibrocell Science Inc.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment